No Data
Cantor Picks 14 Undervalued Biotech Stocks Worth a Second Look
Express News | Rocket Pharmaceuticals Inc : UBS Cuts Target Price to $51 From $54
Rocket Pharmaceuticals Says Blood Disorder Therapies Show Promise
Rocket Pharmaceuticals (RCKT) said Friday that longer-term data on its experimental gene therapies to treat patients with rare blood disorders showed sustained safety and efficacy. Kresladi, a treatme
Rocket Pharmaceuticals Presents Longer-Term Data Updates From Its Lentiviral Vector Hematology Portfolio At ASGCT
Long-term KRESLADI follow-up data demonstrate survival of 100% in the absence of allogeneic hematopoietic stem cell transplantation (HSCT) from 18 to 45 months with a well-tolerated safety profile in
Express News | Rocket Pharmaceuticals Inc - Well-Tolerated Safety Profile in Pkd Patients up to 36 Months After Rp-L301 Treatment
Express News | Rocket Pharmaceuticals Presents Positive Data From Lv Hematology Portfolio at the 27TH Annual Meeting of the American Society of Gene and Cell Therapy (Asgct)